In the human retrovirus system, and more particularly in the human immunodeficiency virus field, very few in vitro systems based on naturally occurring defective strains have been described, although an important role of defective viruses in AIDS pathogenesis has been hypothesized. A very important feature of defective viruses is their ability to interfere with their replication-competent counterparts, rendering defective viruses attractive for the treatment of AIDS.
In our laboratory, the provirus of a non-producer (Federico et at., 1989) , interfering (Taddeo et al., 1993; Federico et al., 1993 Federico et al., a, b, 1995 , human immunodeficiency virus type 1 (HIV-1) variant (F12/HIV), obtained from a cell clone of an Hut-78 cell population infected with an HIV-1 isolate, was Author for correspondence: P. Verani. Fax + 39 6 4453904/4453369. e-mail verani@vbiogen.iss.infn,it cloned and sequenced (Carlini et al., 1992) . Although the F12/HIV genome was not physically defective, the HIV protein pattern detectable in cells expressing this provirus was significantly altered in the Env proteins, which remained in the gp160 precursor form, and in the Gag proteins, whose p55 precursor was poorly cleaved and produced in lower amounts with respect to replication-competent HIV-1 strains (Federico et al., 1989 (Federico et al., , 1995 . It is important to stress that no apparent alterations in HIV RNA expression pattern were observed in cells expressing F12/HIV, thus suggesting that the nonproducer phenotype is not due to defects in virus regulatory sequences and/or genes.
The result of such (and possibly otherl virus protein alterations is that no virus particles, not even aberrant forms, were observed in the supernatants of parental (Hut-78/F12) or other transfected ceils expressing F12/HIV (Federico et a]., 1989 (Federico et a]., , 1993a (Federico et a]., , b, 1995a .
No obvious correlation has been found between the amino acid differences (mostly affecting the gag, poI and vif gene products) detected by sequencing the F12/HIV provirus and the observed non-producer phenotype (Carlini et al., I992) . Thus, new insights into the correlation between HIV genotype and phenotype could be offered by a study of the nonproducer F12/HIV genome. In addition, considering that expression of the F12/HIV genome induces resistance to HIV superinfection and that such a genome may be of use in gene therapy protocols, it is important to estimate the likelihood that recombination events could lead to the conversion of the non-producer F12/HIV phenotype.
In this study, we identified portion(s) of the FI2/HIV genome involved in the non-producer phenotype by exchanging equivalent genomic fragments of F12/HIV and the fully infectious NL4-3 virus genomes. The number and extension of the exchanged genomic regions were limited by the presence of unique restriction sites shared by the two molecular constructs. Nevertheless, the 19 genomic chimeras that we were able to construct and biologically characterize were sufficient to address many unresolved questions.
Two molecular clones were the basis of all genomic chimeras that we constructed: pNL4-3, a pUC18 vector carrying the full genome of an infectious HIV-1 strain (NL4-3) (Adachi et al., 1986) and a pUC19 vector carrying the fulllength non-producer FI2/HIV genome (Carlini et aI., 1992) . All the chimeric molecular clones were sequenced around the manipulated restriction sites in order to exclude the presence of any artefactual alterations due to experimental procedures. Different transfection techniques were performed depending upon the cell type. SupTI cells were transfected by electroporation (1 pg of linearized plasmid DNA per 106 cells; the pulse was 250 V and 960 pF in I x RPMI I640). HeLa CD4 + cells were transfected using the calcium phosphate technique (Wigler et aI., 1979) by adding 2 pg of plasmid DNA to 2 x 10 G cells in 10 cm cell culture dishes. The biological effects of the transfected chimeras on cell cultures were evaluated by direct observation of cytopathic effects, i.e. syncytia formation, and by assaying the reverse transcriptase (RT) activity in the supernatants (Federico et a] ., 1989) and the HIV p24 gag antigen (Antigen Capture assay; Abbott) both in the cytoplasm (Chelucci et aI., 1995) and in the supernatants. We established that a chimera generated a non-producer HIV when, in the absence of both syncytia formation and RT activity in the supernatants, positive values in the Antigen Capture assay were detected a few days after transfection. In fact, in spite of the lack of virion release, Gag protein was easily detected by the Antigen Capture assay in the supernatants of cells expressing F12/HIV. As with cells transfected with the original FI2/HIV genome, cells transfected with the chimeras became negative for p24 expression after cell passage in the absence of any selection pressure. The kinetics of release of p24 in the supematants of HeLa CD4 + cells transfected with two representative chimeras (a producer, F7, and a non-producer, Nd), compared with those from the same cells transfected with either pNL4-3 or FI2/HIV molecular clones, are shown in Fig.  i . Identical results were obtained in transfection experiments performed with both SupT1 and HeLa CD4 + cells.
Of the pNL4-3-based chimeras, only N3 and N6 had a noninfectious phenotype (Fig. 2) . Thus, replacement of either the EcoRI-BamHI fragment or the EcoRI-XhoI fragment (encompassing the whole tat, rev, vpu and env genes and a few nucleotides of the vpr gene) from the NL4-3 genome with the corresponding fragments of Ft2/HIV was sufficient to block HIV NL4-3 infectivity. The HIV released from cells transfected with the N5 chimera (in which NL4-3 pol, vif, most of vpr and the 3' half of gag were replaced with corresponding sequences from the F12/HIV molecular done), while retaining the ability to encode infectious HIV, showed a different phenotype with respect to the parental NL4-3 strain. In fact, when the N5 chimera was transfected in HIV-susceptible cells, it induced the release of an HIV which established a chronic infection with reduced RT activity in the supernatants and an almost complete absence of syncytia formation (data not shown). In addition, the phenotype was conserved when susceptible cells were infected with the supernatants obtained from NS-transfected cultures (not shown). The HIV produced by the N1, N2 and N4 chimeras showed a phenotype identical to that of the parental NL4-3 strain. These results indicate that neither the 5' and 3' LTR regions nor most of the gag gene are directly involved in the F12/HIV non-producer phenotype. As expected, the nonproductivity was retained in the corresponding chimeras constructed on the F12/HIV backbone (F1, F2 and F4).
Of the F12/HIV-based chimeras, only the F7 chimera was infectious. The only fragments of F12/HIV contained in F7 are the LTRs and the gag gene which, as demonstrated by the N1, N2 and N4 chimeras, are all insufficient to convert the producing phenotype.
These results show that, whereas insertion of the EcoRIBamHI F12/HIV fragment was able to block NL4-3 productivity (N3 and N6 chimeras), the homologous region of NL4-3 did not convert the non-infectious F12/HIV phenotype (F3 chimera).
On the basis of the results reported above, we were interested in establishing which part(s) of the F12/HIV EcoRI-BamHt region was sufficient to block NL4-3 infectivity. By combining three different genomic fragments, a second set of six chimeras (Ple-P6e) (Fig. 3) based on the pNL4-3 backbone was constructed. Following the same transfection protocols and the same evaluation criteria described above, we observed that the F I2/HIV EcoRI-StuI region (overlapping the whole vpu gene, the first exons of both the tat and rev genes, the 3' end of the vpr gene and the 5' part of the gp120 env gene) is insufficient to modify the NL4-3 phenotype (Pie chimera). In contrast, the F12/HIV BsaBI-BamHI fragment (encompassing the 3' end of the gp120 env gene, a large part of the gp41 env region and the second exon of the tat and rev genes) induces conversion of the NL4-3 phenotype from infectious to non-infectious, alone (P6e chimera) or in combination with each of the two other fragments (P2e and P4e chimeras). The results obtained by transfecting the chimera encompassing the F12/HIV StuI-BsaBI fragment (which includes a large part of the 3' end of the gp120 env gene) are quite intriguing. In fact, substitution of this fragment induces conversion of the NL4-3 infectious phenotype when substituted alone (PSe chimera) or in combination with the BsaBI-BamHI fragment (already sufficient to convert the NL4- 3 phenotype) (P2e chimera), but no phenotypic changes were observed when it was inserted in the pNL4-3 backbone together with the F12/HIV EcoRI-StuI fragment (P3e). It seems, therefore, that mutations present in the latter genomic region can, in some way, compensate for effects induced by mutations in the former. Analysis of the virus phenotype induced by each chimera was based on transient transfection experiments. Assuming that, since thegag products are HIV 'late' proteins (i.e. they are produced only when the 'early' HIV proteins, such as Tat, Nef and Rev, have been synthesized and are biologically active), the lack of infectious HIV but not of p24 release from transfected cells was due to an intrinsic characteristic of the chimera rather than some possible experimental artefact.
The results obtained suggest that a very large part of the genome (excluding the gag gene, a part of the nef gene and both LTRs) must be replaced in order to convert the FI2/HIV phenotype (F7 chimera): substitution of either of the two parts of this fragment (F5 and F3) was ineffective. Thus, we predict that spontaneous conversion of the F12/HIV genome can be considered a very unlikely event.
Substitution of the whole env gene did not lead to any changes in the F12/HIV genome (F3 chimera); however, NL4-3 infectivity was blocked by a reciprocal exchange (N3 and N6 chimeras). This indicates that: (i) correction of the relatively few mutations in the F12/HIV env gene was not sufficient to induce the phenotype reversion; and (ii) insertion of the same F I2/HIV env alterations was able to block NL4-3 infectivity. In addition, we identified the F12/HIV env regions sufficient to convert the phenotype of an infectious virus genome. The possible effect of some mutations localized in the gpi20 env region could be compensated by mutations in a different part of the same molecule. Conversely, the presence of other F12/HIV gp41 env regions seems to have a 'dominant' effect.
The identification and characterization of other noninfectious HIV have already been described (Boulerice et a] ., I990; Folks et al., 1986; Quillent et al., 1993 (Kim et aI., I993; Lusso et al., 1995) , cells expressing FI2/HIV become resistant to HIV superinfection, even in the absence of CD4 down-regulation (Federico eta] ., 1995 a, b); and (iii) as reported in this paper, the genetic determinants of the F12/HIV nonproducer phenotype are scattered over a very large proviral region and thus do not reside in a single point mutation, as in the case of the HIV genome integrated in 8E5 cells (Gendelman et a] ., 1987) or of non-producing HIV obtained by experimental mutagenesis (Guo eta[., 1990) . Thus, conversion of the FI2/HIV variant to a producer phenotype can be considered a very unlikely event, as also suggested by 8 years of experimentation, where release of infectious H]V particles has not been detected either in parental Hut-78/FI2 cells (Federico et al., I989) , or in any of the cells expressing FI2/HIV obtained so far (Federico et a[., 1993a (Federico et a[., , 1995a . Considering that F12/HIV expression induces protection of the cell host from HIV superinfection, phenotypic stability must be proven if protocols of gene therapy experiments are to be planned using large parts of the F12/HIV genome.
